SABA, ELENA
SABA, ELENA
Universita' degli Studi di MILANO
PU.1-Activated Genomic Regions Define Low-risk MDS Subsets Characterized by Immune Dysregulation and Disease Progression
2026 V. Vallelonga, F. Gandolfi, M. Zampini, E. Riva, G. Maggioni, D. Ventura, E. Saba, A. Termanini, S. Polletti, E. Prosperini, L. Crisafulli, A. Campagna, I. Ferrari, N. Pinocchio, G. Todisco, S. Pedretti, M. Calvi, C. Di Vito, D. Mavilio, N. Mitro, F. Ficara, M.G. Della Porta, S.M.L. Ghisletti
Disrupted innate lymphoid cell development shapes prognosis and therapy outcomes in myelodysplastic syndrome patients
2025 L. Orlandi, M. Calvi, A. Frigo, E. Riva, G. Maggioni, A. Russo, E. Saba, M. Ubezio, M. Giovanni Della Porta, C. Di Vito, D. Mavilio
Deciphering the role of immune system dysfunction in patients with Myelodysplastic Syndrome to refine the prognostic assessment and predict treatment response
2025 C. Di Vito, M. Calvi, E. Riva, M. Zampini, L. Dall’Olio, A. Merlotti, M. Ubezio, A. Russo, G. Maggioni, A. Frigo, L. Orlandi, E. Saba, D. Remondini, G. Castellani, G. Della Porta Matteo, D. Mavilio
DECIPHERING THE ROLE OF IMMUNE SYSTEM DYSFUNCTION IN MYELODYSPLASTIC SYNDROMES CLASSIFICATION AND PROGNOSIS
2024 E. Riva, M. Calvi, M. Zampini, L. Dall’Olio, A. Merlotti, A. Russo, G. Maggioni, A. Frigo, E. Saba, E. Lugli, D. Remondini, G. Castellani, C. DI VITO, D. Mavilio, M.G.D. Porta.
Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Rene Prognostic Assessment and Predict Treatment Response
2024 E. Riva, M. Calvi, M. Zampini, L. Dall'Olio, A. Merlotti, A. Russo, G. Maggioni, L. Orlandi, A. Frigo, F. Ficara, L. Crisafulli, E. Sauta, S. D'Amico, E. Lugli, A. Campagna, M. Ubezio, C. Astrid Tentori, G. Todisco, L. Lanino, A. Buizza, D. Ventura, N. Pinocchio, E. Saba, A. Santoro, V. Santini, A.A. van de Loosdrecht, R.S. Komrokji, G. Garcia-Manero, P. Fenaux, L. Ades, U. Platzbecker, T. Haferlach, A. Medina Almeida, A.M. Zeidan, S. Kordasti, D. Remondini, G. Castellani, C. DI VITO, D. Mavilio, A. Matteo Giovanni Della Porta
The immunome profile of myelodysplastic syndrome patients defines different prognostic groups and shows a predictive potential to hypomethylating therapy
2023 M. Calvi, E. Riva, M. Zampini, L. Dall’Olio, A. Merlotti, A. Russo, G. Maggioni, A. Frigo, E. Saba, D. Remondini, G. Castellani, C. DI VITO, M. Giovanni Della Porta, D. Mavilio
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the "Health and Anemia" Study
2018 M. Rossi, M. Meggendorfer, M. Zampini, M. Tettamanti, E. Riva, E. Saba, N. Manes, C. Milanesi, U. Marta, L. Morabito, E. Travaglino, C. Peano, G. Solda, R. Asselta, S. Duga, K. Malik, C.F. Selmi, E. Civilini, S. Mandelli, N. Bolli, G.S. Vassiliou, W. Kern, A. Santoro, U. Lucca, T. Haferlach, M. Giovanni Della Porta
A Peculiar Formula of Essential Amino Acids Prevents Rosuvastatin Myopathy in Mice
2016 G. D'Antona, L. Tedesco, C. Ruocco, G. Corsetti, M. Ragni, A. Fossati, E. Saba, F. Fenaroli, M. Montinaro, M. Carruba, A. Valerio, E. Nisoli
Functional variations modulating PRKCA expression and alternative splicing predispose to multiple sclerosis
2014 E.M. Paraboschi, V. Rimoldi, G. Soldà, T. Tabaglio, C. Dall'Osso, E. Saba, M. Vigliano, A. Salviati, M. Leone, M.D. Benedetti, D. Fornasari, J. Saarela, P.L. De Jager, N.A. Patsopoulos, S. D'Alfonso, D. Gemmati, S. Duga, R. Asselta
Transcriptional dysregulation and impairment of PHOX2B auto-regulatory mechanism induced by polyalanine expansion mutations associated with congenital central hypoventilation syndrome
2013 S. Di Lascio, T. Bachetti, E. Saba, I. Ceccherini, R. Benfante, D. Fornasari
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells
2013 C. Carlo-Stella, S.L. Locatelli, A. Giacomini, L. Cleris, E. Saba, M. Righi, A. Guidetti, A.M. Gianni